Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.
Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Sonpavde G, et al. Among authors: fleming mt. Urol Oncol. 2011 Nov-Dec;29(6):682-9. doi: 10.1016/j.urolonc.2009.09.015. Epub 2009 Dec 3. Urol Oncol. 2011. PMID: 19959380 Clinical Trial.
Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Beer TM, et al. N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1. N Engl J Med. 2014. PMID: 24881730 Free PMC article. Clinical Trial.
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
de Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, Hinrichs MJ, Zhang Q, He P, Williams M, Rosenbaum AI, Liang M, Vashisht K, Cho S, Martinez P, Petrylak DP. de Bono JS, et al. Among authors: fleming mt. Clin Cancer Res. 2021 Jul 1;27(13):3602-3609. doi: 10.1158/1078-0432.CCR-20-4528. Epub 2021 Apr 1. Clin Cancer Res. 2021. PMID: 33795255 Clinical Trial.
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, Rasmussen J, Milowsky MI, Fleming MT, Bearden J, Goodman M, Zhang T, Harrison MR, McNamara M, Zhang D, LaCroix BL, Kittles RA, Patierno BM, Sibley AB, Patierno SR, Owzar K, Hyslop T, Freedman JA, Armstrong AJ. George DJ, et al. Among authors: fleming mt. Cancer. 2021 Aug 15;127(16):2954-2965. doi: 10.1002/cncr.33589. Epub 2021 May 5. Cancer. 2021. PMID: 33951180 Free PMC article.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. de Bono JS, et al. Among authors: fleming mt. Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10. Lancet Oncol. 2021. PMID: 34388386 Free article. Clinical Trial.
Trial design for metastatic castration-resistant prostate cancer.
Sonpavde G, Fleming MT, Hutson TE, Galsky MD. Sonpavde G, et al. Among authors: fleming mt. J Clin Oncol. 2008 Jul 20;26(21):3647-8; author reply 3648-9. doi: 10.1200/JCO.2008.17.1140. J Clin Oncol. 2008. PMID: 18640946 No abstract available.
46 results